 |
인쇄하기
취소
|
Ilyang to conduct Phase 2 study of new leukemia dug in India, Thailand
Ilyang Pharm said on April 15 that it will soon begin Phase II clinical trial for its new leukemia drug in India and Thailand.
Developed by Ilyang, the drug is believed to be 30 times more potent than Glivec, a popular anti-leukemia medicine. If successful, it is expected to change the landscape of the leukemia drug market.
A research team at Seoul St. Mary's Hospital's hematopoetic stem ...
Developed by Ilyang, the drug is believed to be 30 times more potent than Glivec, a popular anti-leukemia medicine. If successful, it is expected to change the landscape of the leukemia drug market.
A research team at Seoul St. Mary's Hospital's hematopoetic stem ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.